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Abstract
Oxidative stress has been implicated in epilepsy and various neurodegenerative disor-
ders. In this review, we elaborate oxidative stress-mediated neuronal loss and assess 
the role of selenium in some neurological disorders including epilepsy. Selenium as 
an essential trace element has attracted the attention of many researchers because of its 
potentialities in human health. It has an important role in the brain, immune response, 
defense against tissue damage, and thyroid function. Selenium forms part of the active 
site of the peroxide-destroying enzyme glutathione peroxidase (GSHPx), and it also has 
other functions, for example in biotransformation and detoxification. Functional and 
clinical consequences of selenium deficiency states in neurological diseases have been 
described, and the selenium requirement, which is influenced by various processes, has 
been discussed. Wide variations have been found in selenium status in different parts 
of the world, and populations or groups of patients exposed to marginal deficiency are 
more numerous than was previously thought. Chronic diseases, such as neurological 
disorders, heart disease, diabetes, cancer, aging, and others, are reported to associate 
with markers of oxidative damage. It is, therefore, not unreasonable to suggest that 
antioxidants would alleviate the oxidative damage, resulting in health improvements. 
In recent years, accumulated evidence in nutrigenomics, laboratory experiments, clinical 
trials, and epidemiological data have established the role of selenium in a number of 
conditions. Most of these effects are related to the function of selenium in the antioxidant 
enzyme systems. Current research activities in the field of human medicine and nutrition 
are devoted to the possibilities of using selenium as an adjuvant for the treatment of 
degenerative or free radical diseases such as neurological disorders, inflammatory dis-
eases, and cancer.
Keywords: selenium, antioxidants, oxidative stress, pathogenesis of neurological 
disorders
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1. Introduction
Selenium is a trace mineral essential to human health, which has an important role in the 
immune response, defense against tissue damage, and thyroid function. Improving sele-
nium status could help protect against overwhelming tissue damage and infection in criti-
cally ill adults [1–4]. Selenium is incorporated into proteins to make selenoproteins, which 
are important antioxidant enzymes. The antioxidant properties of selenoproteins help pre-
vent cellular damage from free radicals. Free radicals are natural by-products of oxygen 
metabolism that may contribute to the development of chronic diseases such as cancer and 
heart disease [5, 6]. There is evidence that selenium deficiency may contribute to develop-
ment of a form of hypothyroidism and a weakened immune system. Specific diseases have 
been associated with selenium deficiency such as Keshan and Kashin-Beck disease, which 
results in osteoarthropathy and myxedematous endemic cretinism, which results in mental 
retardation [7, 8].
In recent years, considerable evidence has emerged implicating a role for oxygen free radicals 
in the initiation of cellular injury which can lead to the development of several neurological 
disorders. The neonatal brain, with its high concentrations of unsaturated fatty acids (lipid 
content), high rate of oxygen consumption, and low concentrations of antioxidants, is particu-
larly vulnerable to oxidative damage. Thus, increased oxidative stress has been implicated in 
various neurological disorders such as seizures, ischemia-reperfusion injury, and neurode-
generative diseases [9, 10] such as Alzheimer’s, Parkinson’s, and Lou Gehrig’s disease. Free 
radical damage has been implicated in the initiation and propagation of seizure activity as 
well as the accompanying seizure-induced neuronal damage [11]. Therefore, antioxidants 
could play an important role in modulating susceptibility to seizure activity and seizure-
induced neuronal injury.
The use of selenium as a supplement in neurological disorders has been reported. The ratio-
nale for selenium supplementation comes from the nutrient’s role as an antioxidant [12], 
working primarily as a component of glutathione peroxidase, an important cellular protector 
against free radical damage. Furthermore, selenium deficiency is known to result in neu-
romuscular disease. Attempts have been taken to relate selenium to different neurological 
disorders as epilepsy, phenylketonuria and maple syrup urine disease, Parkinson’s disease, 
amyotrophic lateral sclerosis, neuronal ceroid lipofuscinoses, myotonic dystrophy, multiple 
sclerosis, Down syndrome (DS), and Alzheimer’s disease [13, 14]. The relevant connection 
between selenium and the majority of these disorders rests on clinical observations during 
selenium supplementation alone or in combination with other antioxidants.
2. Selenium distribution in humans
Due to the uneven geographic distribution of selenium in soil, the amount of whole-body sele-
nium in adult humans was reported to differ in different countries [15–18]. At normal dietary 
levels, the highest selenium concentration was detected in reindeer liver and kidney, followed 
Personalized Medicine, in Relation to Redox State, Diet and Lifestyle162
by the spleen, pancreas, heart, brain, lung, bone, and skeletal muscle. Selenium concentration 
in the human body was also found to vary with age. For instance, selenium concentration 
in fetal brain decreased with age but increased with age postnatally. Blood selenium levels 
were negatively correlated with age in healthy adults, and the same was documented for 40 
patients with dementia of the Alzheimer type (DAT). Furthermore, Ejima et al. [19] reported 
that selenium concentrations varied in different adult human brain regions.
3. Selenium in the brain
Neurochemical aspects of selenium have been widely reported. In this approach to the etio-
pathogenetic role of selenium in CNS diseases, teleological ideas are explicitly correlated to 
the paradigm of oxygen toxicity. The brain differs from many other tissues, being a highly 
aerobic and totally oxygen-dependent tissue. Oxygen reduction produces reactive radical 
intermediates, i.e., singlet oxygen, a superoxide radical which is thought to be a major agent of 
oxygen toxicity. Hydrogen peroxide, H
2
O
2
, is formed through dismutation of a singlet oxygen 
catalyzed by Cu-Zn and Mn forms of superoxide dismutase, both found in CNS tissues. Other 
hydrogen peroxide-generating enzymes are associated with d- and l-amino acid oxidase, 
monoamine oxidase, a-hydroxyacid oxidase, xanthine oxidase, and cytochrome P-450 system.
Unlike charged oxygen radicals being a rather unreactive and stable, H
2
O
2
 rapidly crosses cell 
membranes. Cellular damage is accomplished when H
2
O
2
 decomposes to the highly reactive 
hydroxyl radical in iron(II) or copper(I) catalyzed reactions. Scavenging of H
2
O
2
 and contem-
poraneous prevention of hydroxyl radical formation occurs predominantly at two cellular 
sites, in the peroxisomes and in the cytoplasm by catalase and GSHPx (GSHPx, glutathione/
hydrogen peroxide oxidoreductase, EC 1.11.1.9), respectively. If this is not done, the hydroxyl 
radical may attack the fatty acid side chains and start a chain reaction of lipid peroxidation. 
Lipid peroxidation causes gradual loss of membrane fluidity and membrane potential and 
increases membrane permeability to ions. Radical attack may also destroy membrane-bound 
enzymes and receptors, e.g., the binding of serotonin is decreased. Oxidative degradation 
and polymerization of lipids leads to the accumulation of lipofuscin, the age pigment. The 
presence of catalytic iron and copper complexes in human CSF, and the high iron content of 
brain, suggests that they are very sensitive to oxygen radical generation.
The crucial role of selenium as a trace element in the nervous tissue has been associated 
with a selenoenzyme glutathione peroxidase. Selenium is thought to be present at the 
active site of GSHPx in its selenolate form as selenocysteine [20]. The fairly homogenous 
distribution of selenium in the human brain corresponds well with the regions of the high-
est and lowest GSHPx activity found in the rat brain. However, estimates of the amounts 
of selenium in rat brain have indicated that GSHPx may account for only 1/5 of the total Se 
found in the brain [21]. Most of the selenium is bound to proteins and not to amino acids or 
nucleic acids [22]. Selenoproteins, other than GSHPx, found in the brain and the reproduc-
tive and the endocrine organs seem to serve as a priority pathway of the element during 
inadequate selenium intake. The function of selenium in proteins has been explained in 
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terms of semiconduction [23]. It is possible although not yet proven that selenium may have 
this or some other special functions outside of GSHPx too.
Observations suggest that free radical intermediates may be involved in the coupling between 
depolarization of the plasma membrane, Ca2+ fluxes, and neurotransmitter release [24]. In gen-
eral, cellular redox adjustments regulate functional sulfhydryl groups of proteins. Therefore, 
cellular prooxidant states may be involved in the generation of physiological responses. This 
means that the adjustment of redox equilibrium in CNS is a far more delicate phenomenon 
than just a tendency to a normal balance.
The regulation of GSH level (GSH/GSSG) through pentose phosphate pathway producing 
NADPH, GSH-reductase, and GSHPx contributes to the overall redox state of cells in the 
brain [25]. The brain tends to need radical reactions as well as to possess specific or high 
endogenous levels of free radical scavengers such as dopamine, norepinephrine, and cat-
echol estrogens, taurine and carnosine [26], in neurons. Carnosine is involved with GSBA 
activity in the brain, and a study by Takahashi [27] demonstrated that homocarnosine levels 
were high in patients who responded to antiepileptic drugs. The functional balance between 
various free radical scavenger systems in the brain seems reasonable. Significant positive 
correlations between catalase and SOD levels have been reported in tissues of normal sub-
jects excluding erythrocytes. Factors concomitantly influencing the variation of the activities 
of SOD, catalase, and GHSPx have been reported. Enzymes frequently called a protective 
should rather be envisaged as being regulatory, controlling the levels of different states of 
oxygen reduction.
4. Brain antioxidant homeostasy in relation to selenium and GSHPx
As a trace element in nature, the availability of selenium may be limited. GSHPx activity has 
been shown to reflect selenium status in deficient and adequate states [6]. On the other hand, 
protection against toxicity is likely to involve the alterations in GSH metabolism that occur 
in nutritional Se deficiency. High concentrations of erythrocyte glutathione in patients with 
neurological disorders have been reported [28]. However, regulatory mechanisms apparently 
exist which ensure that during periods of insufficient selenium intake, the content of the ele-
ment is kept up above all in the brain and the reproductive and endocrine organs.
Yoshida et al. [29] reported a comprehensive method for identifying the selenium-binding 
proteins using PenSSeSPen as a model of the selenium metabolite, selenotrisulfide (RSSeSR, 
STS), which was applied to a complex cell lysate generated from the rat brain. The authors 
stated that a thiol-containing protein at m/z 15155 in the brain cell lysate was identified as the 
cystatin-12 precursor (CST12) from a rat protein database search and a tryptic fragmentation 
experiment. CST12 belongs to the cysteine proteinase inhibitors of the cystatin superfamily 
that are of interest in mechanisms regulating the protein turnover and polypeptide produc-
tion in the central nervous system and other tissues. Consequently, CST12 is suggested to be 
one of the cytosolic proteins responsible for the selenium metabolism in the brain [29].
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Selenium seems to be somehow involved in the regulation of oxygen metabolism through its 
influence on a variety of enzymes. In concentrations of 6 × 10−7 to × 10−6 M, selenite induces a 
30-fold increase of GSHPx activity in neuroblast cells in vitro. Other studies with the rat liver 
have suggested that Se status regulates the level of GSHPx mRNA as well as regulates GSHPx 
protein concentration and GSHPx activity [30]. In concentrations of 0.7–2 × 10−5 M, Se in rat 
liver increases the activities of g-glutamylcysteine synthetase, the first rate-limiting enzyme in 
GSH biosynthesis, and GSSG-reductase, which catalyzes the reduction of GSSG to GSH [31]. In 
some species the induction of GSH-S-transferase has been shown to occur as a result of Se defi-
ciency. H
2
O
2
 as the most stable and diffusible of the oxygen reduction intermediates may exert 
an influence on the expression of SOD, catalase, and GSHPx activities. GSHPx, which exists in 
several forms that differ in their primary structure and localization, catalyzes the reduction of 
hydrogen peroxide and organic hydroperoxide by glutathione and functions in the protection 
of cells against oxidative damage [32]. The homeostasy in the oxidative metabolism and oxygen 
reduction may be distorted by different means, either inherent or acquired. Depending on the 
spatial and temporal occurrence of the distortion, various neurological states are expressed.
The developing brain is particularly susceptible to oxidative stress, more so than the mature 
brain [33]. H
2
O
2
 accumulation has also been associated with increased injury in superoxide 
dismutase-overexpressing neonatal murine brain, and greater cell death is seen when imma-
ture neurons are exposed to H
2
O
2
 than mature neurons. Increased H
2
O
2
 accumulation may be 
the result of relative insufficiency of the endogenous enzyme GSHPx.
Under physiologic circumstances, the brain has efficient antioxidant defense mechanisms, 
including GSHPx, which converts potentially harmful H
2
O
2
 to oxygen and water at the 
expense of reduced GSH. Under oxidative stress, in the immature brain, endogenous levels 
of GSHPx may be inadequate for converting excess H
2
O
2
. Transgenic mice that overexpress 
GSHPx (hGPx-tg), when subjected to hypoxic-ischemic (HI), have less histologic brain injury 
than their Wt littermates [25]. In addition, the cortex exhibits increased GSHPx enzyme activ-
ity at 24 h, whereas GSHPx activity remains unaltered in the Wt brain. In addition, neu-
rons cultured from GSHPx-tg brain are resistant to injury from exogenously applied H
2
O
2
 
[34]. Neurons cultured from the hippocampus and cortex that are transfected (transfection 
describes the introduction of foreign material into eukaryotic cells) with genes for catalase 
and GSHPx also show protection from neurotoxic insults and a corresponding decrease in 
H
2
O
2
 accumulation [35]. These findings indicate that adequate GSHPx activity can ameliorate 
injury to the immature brain from oxidative stress due to H
2
O
2
.
It is well established that previous stress to the brain can induce tolerance to subsequent 
injury, a phenomenon called personality change (PC). In neonatal rodents, protection against 
HI brain injury has been induced by PC with a period of hypoxia before the induction of 
HI [36]. The mechanisms of this protection have yet to be fully determined, but it has been 
established that a large number of genes are induced in response to hypoxia [37]. Several 
of these genes are regulated by the transcription factor hypoxia-inducible factor-1α (HIF-1α) 
and perhaps most importantly vascular endothelial growth factor (VEGF) and erythropoietin 
(EPO). VEGF is upregulated after focal ischemic injury in the neonatal rat, in parallel with 
induction of HIF-1α [38, 39].
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5. Aging, dementia, and Alzheimer’s disease
Major interest in CNS selenium is related to aspects of oxidative stress and aging. The 
decrease in cerebral blood flow, glucose utilization, and oxygen consumption common to 
many dementias results from abnormalities of brain structure with a high oxidative capacity. 
During mental activity, regional cerebral oxidative metabolism and regional cerebral blood 
flow increase in several areas of the brain. In dementia of the Alzheimer type, brain blood flow 
and oxidative metabolism are reduced. This situation may lead to loss of balance between 
prooxidants and antioxidants [40]. The role of H
2
O
2
 in the etiology of Alzheimer’s disease 
has been reported [41, 42]. Furthermore, the activities of catalase and GSHPx decrease with 
aging in intact animals. Some reports suggest that the SOD activity is significantly greater in 
Alzheimer cell fibroblasts. Both GSHPx and SOD activities in the erythrocytes of AD have 
been reported to be normal, while other studies show significantly higher erythrocyte SOD 
level in AD [43]. It remains to be seen whether oxidative damage will still be related to the 
accumulation of aluminum silicates in the brain as well as to that of the senile plaques and 
tangles. Experiments have indicated that aluminum salts may not only accelerate Fe(II)-
induced peroxidation of membrane lipids but do this especially in the brain [44, 45].
In order to evaluate the peroxidative stress in dementias, autopsy brain samples should be 
studied for GSHPx, SOD, catalase, and selenium. A direct causal relationship between brain 
antioxidant defenses and dementia in aging and Alzheimer’s disease is hard to demonstrate 
because of the extremely slow process. Interestingly a high proportion of Down syndrome 
patients develop the neuropathological and clinical changes of AD, suggesting a close patho-
genetic relationship between these disorders. Thus, the correction of antioxidant balance in 
AD by Se supplementation should be demonstrated by other means so as to direct it preven-
tatively to those with a high risk of developing AD.
In Alzheimer’s disease the H
2
O
2
 molecule should be considered a therapeutic target for treat-
ment of the oxidative stress associated with the disease. The actions of H
2
O
2
 include modifica-
tion of DNA, proteins, and lipids, all of which are effects seen in an Alzheimer’s disease brain, 
possibly contributing to the loss of synaptic function characteristic of the disease. Future 
research and development of agents that specifically target the H
2
O
2
 molecule or enzymes 
involved in its metabolism may provide the future route to Alzheimer’s disease therapy [42].
6. Down syndrome
Trisomy 21 (Down syndrome) is the most common genetic cause of learning disability in 
humans [46], occurring in about 1 per 1000 babies born each year [47]. Postmortem studies 
have reported neuronal depletion and structural abnormalities of the brain during late gesta-
tion and early postnatal life [48]. Down syndrome was found to have increased activity of 
superoxide dismutase without a compensatory increase in glutathione peroxidase activity 
[49]. However, there is no evidence to support the use of antioxidant or folinic acid supple-
ments in children with Down syndrome [50].
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Increased primary gene products which may contribute to the pathology of DS include cyto-
plasmic CuZn-superoxide dismutase (SOD). Consistent with the gene dosage effect, SOD 
activity is increased by 50%, leading to noxious concentrations of H
2
O
2
, while brain GSHPx 
remains normal. The overall redox state in other tissues is corrected by an adaptive increase 
of GSHPx activity. This means that the brain is especially susceptible to oxygen free radical 
stress. Our primary survey of specific antioxidant therapy with selenium [51] rests on this 
theory.
The whole-body retention of 5–8 kBq 75Se-sodium selenite with 0.4 g Se as carrier/kg body 
weight in DS patients has been earlier estimated to be 53.3 + 21.1%. Stable Se supplementation 
increased 75Se elimination, indicating a saturated Se pool in the body. Twenty-four patients 
aged 1–41 years were either given selenium supplements of 0.025 mg Se/kg/d in the form of 
sodium selenite or given placebo or no preparation. The serum levels of selenium indicated no 
real deficiency as compared to the normal healthy population. However, the mean compensa-
tory increase of erythrocyte GSHPx activity before supplementation was lower than expected. 
Because of difficulties in obtaining brain biopsies, variables found in the plasma and erythro-
cyte samples were used as indicators of antioxidant balance. Sinet et al. [52] have reported a 
high positive correlation between erythrocyte GSHPx values and the intelligence quotient in DS 
patients. Because of this and the difficulties in testing changes of IQ which is one of the most deci-
sive clinical goals of therapy, we found it reasonable to follow changes of E-GSHPX. Selenium 
supplementation increased E-GSHPx activity by 28% (59.9% above normal). The correction is 
sensitive to adequate Se supplementation as indicated by SOD/GSHPx index which decreased 
by 23.9% (P < 0.01) [51]. Interestingly the primarily high serum and blood mononuclear cell 
levels of cupric and ferrous ions decreased, and that of zinc ions increased during supplementa-
tion. In conclusion we believe that the patients have benefited from the selenium supplementa-
tion through optimization of their antioxidant protection by GSHPx.
7. Selenium and epilepsy
An epilepsy syndrome is a complex of signs and symptoms defining a unique condition [53]. 
Oxidative stress and generation of reactive oxygen species are strongly implicated in a num-
ber of neuronal and neuromuscular disorders, including epilepsy. The functions of selenium 
as an antioxidant trace element are believed to be carried out by selenoproteins that possess 
antioxidant activities and the ability to promote neuronal cell survival. Selenoproteins are 
important for normal brain function, and decreased function of selenoproteins may lead to 
impaired cognitive function and neurological disorders [54].
Free radicals and lipoperoxidation reactions seem to be involved in epileptic seizure devel-
oping after brain hemorrhage of different kinds. There is an association between hemosid-
erin deposition and post-traumatic epilepsy. An extravasation of blood and hemolysis of 
erythrocytes result in the decompartmentalization of free iron and accelerate the rates of 
lipoperoxidation and superoxide-dependent formation of OH radicals, which are propagated 
by reperfusion and reoxygenation in postischemic tissue injury. Simultaneously the activity 
of GSHPx in the ischemic tissue is decreasing. Selenium and other antioxidants have been 
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observed to prevent synergistically the lipoperoxidation in animals and in man. Pretreatment 
of rats with vitamin E and selenium prior to iron injections has been shown to prevent the 
development of seizures to a high degree in a large percentage of experimental rats [55]. 
There are also reports of the normalization of the EEG of patients with the juvenile type of 
neuronal ceroid lipofuscinosis (JNCL) after vitamin E and sodium selenite supplementation. 
In addition, the onset of epilepsy is significantly earlier among JNCL patients not given this 
antioxidant therapy (11.1 year) than patients receiving antioxidant therapy (13.6 year) [56].
Numerous evidences suggest that selenium may ameliorate some of the adverse metabolic 
consequences of valproic acid. Valproic acid therapy has been shown to deplete plasma sele-
nium levels, a cofactor required for glutathione peroxidase activity. Selenium supplement 
may help lower ammonia level in patients with valproate-induced hyperammonemia over 
long-term treatment. Selenium deficiency may lead to the loss of seizure control, even when 
the patient is remained on the same dose of valproic acid [57, 58]. Furthermore, Ashrafi et al. 
[59] concluded that the measurement of serum selenium in patients with intractable epilepsy 
should be considered.
8. Juvenile type of neuronal ceroid lipofuscinosis
The neuronal ceroid lipofuscinoses (NCL) are a group of recessively inherited neurodegener-
ative-lysosomal storage diseases of infancy, with an estimated occurrence of 1 in 12,500 live 
births [60–62]. Characteristics of the diseases are deposits of ceroid and lipofuscin pigments 
in the tissues, particularly in the neural tissue, visual failure, and progressive mental retarda-
tion. Depending on the age of onset and clinical, electrophysiological, and neuropathological 
features, the NCLs can be subdivided into the infantile, the late infantile, the juvenile, and the 
adult type of NCL. The pathogenesis of NCL is unknown. The polyenic acid level with low 
levels of linoleic acid and an inverse relationship between GSHPx activity and the level of 
eicosatrienoic acid has been observed in JNCL [63].
The occurrence of the fluorescent pigments suggested the peroxidation of lipids in the etiology of 
NCL. It is likely that the diseased tissues peroxidize more rapidly than normal tissues and cyto-
toxic end products of lipoperoxidation cause secondary damage. On a weight basis, ceroid seen 
in JNCL patients binds five times more iron than the lipofuscin seen in normal elderly individu-
als. The increased levels of aluminum salts greatly enhance iron-dependent damage to mem-
branes. Heiskala et al. [64] have confirmed the presence of complexable iron and copper in the 
CSF of patients with NCL and other neurological disorders, and when the pH value of the assay 
for iron was lowered, the NCL group had substantially more complexable iron in their CSFs. 
Interestingly aluminum has been observed in CSF and in ceroid lipofuscin pigments of the brain 
of NCL patients [65]. It is well established that damaged tissue releases metals from protein-
bound sites and these metals stimulate peroxidative damage to lipids and other biomolecules.
One of the most essential enzymes counteracting lipoperoxidation is the selenium-containing 
GSHPx. Two independent reports have demonstrated that erythrocyte GSHPx activity is 
decreased in JNCL patients [66, 67]. This low GSHPx activity was reversed to normal level by 
selenium supplementation.
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The evaluation of sodium selenite absorption and losses before supplementation of JNCL 
patients has been studied by using total body counting for 75Se detection. These studies showed 
that in three JNCL patients, about 55% of the administered 75Se was eliminated during the 
first 11 days in the feces and about 10% in the urine [68]. Compared to healthy controls (n = 
2, percentages 42% and 7%, respectively), findings indicate a reduced absorption of selenium 
in JNCL patients contrary to a previous report. The low GSHPx activity in NCL patients may 
indeed reflect a low selenium intake, most probably due to a disturbed absorption of selenium 
and secondary phenomena due to an inborn error of metabolism. Apart from the low selenium 
status, also very low vitamin E levels are found in the serum of advanced and hospitalized 
NCL patients. This can be explained by the recent finding of a pronounced reduction of apo-
protein B as well as the whole fraction of very low density lipoprotein (VLDL) in JNCL patients.
JNCL patients (genetically subgroups) have been given daily supplementation of sodium 
selenite (0.05–0.1 mg/Se/kg of b.w.), vitamin E (α-tocopherol acetate 0.014–0.05 g/kg b.w.), 
vitamin B
2
 (0.025–0.05 mg/kg b.w.), and vitamin B
6
 (0.63–0.8 mg/kg b.w.). The benefits of 
the therapy are corroborated by the significant negative correlation of GSHPx activity with 
neurological dysfunction of motor performance, balance, coordination, and speech [69]. The 
mean age at death has been extended by 4 years as compared to that at the beginning of 
the century. As the best responders to antioxidant therapy show no neurological dysfunc-
tion at the age of over 20 years, there is no doubt that the life expectancy of JNCL patients 
receiving antioxidants, including selenium, will be significantly prolonged in the future [70]. 
Complications of the antioxidant therapy have been few and not severe. Six patients have 
experienced vomiting and nausea when the serum concentration of selenium reached the 
level of 4.5–5 M. Serum levels up to 4.0 M were usually well tolerated as well as when the 
sodium selenite was changed to EbselenR (2-Phenyl-1,2-benzoselenazol-3-one).
9. Multiple sclerosis (MS)
Multiple sclerosis is a severe neurodegenerative disease of polygenic etiology affecting the 
central nervous system. Low levels of polyenic acids are involved in the pathogenesis of both 
MS and JNCL [71, 72]. In 1972 Thompson et al. found decreased levels of serum linoleate as 
well as unsaturated fatty acids of brain phospholipids in MS patients. It has also been shown 
that supplementation with essential fatty acids may improve the clinical status of young MS 
patients diagnosed early. As in NCL, the selenium may by activating GSHPx (scavenger of 
organic peroxides) regulate the metabolic transformation of essential fatty acids and biotrans-
formation of these to prostaglandins, thromboxanes, and leukotrienes. Curiously decreased 
GSHPx activities in erythrocytes have been found in female but not in male MS patients [73].
Blood selenium levels have been reported to be lower in MS patients than in healthy con-
trols [74–76]. However, selenium concentration has been shown to be normal in plasma and 
erythrocytes but lowered in platelets of MS patients. Impaired Se status has been found in 
MS largely in the connection of severe protein-calorie malnutrition. Treatment of MS with Se 
supplementation does not seem warranted in the absence of demonstrated deficiency. Thus, 
in the reported selenium-containing antioxidant treatments, the clinical benefit to the course 
of MS has remained open to speculation.
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10. Neurotoxicity
10.1 Mercury intoxication
Mercury is well known for its severe toxicity especially by inhalation [77]. People exposure 
to Hg is mainly due to environmental pollution and the consumption of fish or other aquatic 
product [78]. Chronic mercury poisoning is characterized by neurological and psychological 
symptoms, such as tremor, restlessness, personality changes, anxiety, sleep disturbance, and 
depression. Symptoms are reversible after cessation of exposure. Because of the blood-brain 
barrier, there is no central nervous involvement related to inorganic mercury exposure [79]. 
Selenium interacts in the body with a wide range of toxic metals such as arsenic, cadmium, 
mercury, copper, silver, and lead. It has been shown to be highly effective in animals in pre-
venting brain damage of organic and inorganic mercury. In postmortem brain samples from 
persons exposed to mercury vapors, mercury and selenium were found at a molar ratio of 
approximately 1. This indicates that the brain is the target organ in human exposure to mer-
cury vapors. Mercury and selenium react in various ways. The role of brain selenium in inor-
ganic heavy metal toxicity is thought to be minimal [80, 81]. Mercuric ion bound to selenium 
is proposed to form a biologically inert complex, leading to increased body burden of both 
elements. This reaction seems to take place only when a threshold of mercury exposure is 
exceeded. Selenium influences the oxidation rate of elemental mercury in cases of low GSHPx 
activity; decreased mercury oxidation may lead to increased brain uptake. Selenium may also 
together with vitamin E counteract mercury-induced lipid peroxidation.
11. Other CNS diseases related to selenium
11.1 Parkinson’s disease
Parkinson’s disease (PD) is a chronic and progressive movement disorder, meaning that 
symptoms continue and worsen over time. Oxidative stress is also thought to have a patho-
genic role in Parkinson’s disease [82, 83]. Selenium protects cellular elements from oxidative 
damage and may participate in redox-type reactions. Low plasma selenium concentrations 
are associated with subtle neurological impairments reflected in soft neurological signs [84, 
85]. Plasma Se was the only statistically significant difference of up to 16 elements identified 
for PD patients [86] relative to Alzheimer's disease patients. Redox-active role is evidenced 
by an increased lipid peroxidation and reduced glutathione levels [87] and high concentra-
tion of iron and free radical generation via autocatalytic mechanisms within neuromelanin-
containing catecholaminergic neurons in the substantia nigra. In addition, the observation 
that exogenous administration of cysteine, N-acetyl cysteine, or glutathione decreased the 
neurotoxic effects of 6-hydroxydopamine in vitro and in vivo reinforces this hypothesis [88].
11.2 Tardive dyskinesia
Tardive dystonia (TD), a rarer side effect after longer exposure to antipsychotics, is character-
ized by local or general, sustained, involuntary contraction of a muscle or muscle group, with 
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twisting movements, generally slow, which may affect the limbs, trunk, neck, or face [89, 90]. 
This condition is characterized by involuntary movements. These abnormal movements most 
often occur around the mouth. The disorder may range from mild to severe. For some people, 
it cannot be reversed, while others recover partially or completely. Tardive dyskinesia is seen 
most often after long-term treatment with antipsychotic medications. Other names for this 
specific disorder are linguofacial dyskinesia, oral-facial dyskinesia, tardive dystonia, tardive 
oral dyskinesia, and TD. Many preclinical and clinical studies have investigated the possible 
role of selenium and other antioxidants. These studies suggest that free radicals are probably 
involved in the pathogenesis of TD and that vitamin E and selenium could be efficacious in 
its treatment.
11.3 Duchenne muscular dystrophy
Muscular dystrophy (MD) is a group of genetic diseases involving progressive weakness and 
degeneration of the muscles that control movement. In some forms of MD, the heart muscles 
and other involuntary muscles, as well as other organs, are also affected. There are nine 
distinct types of MD, with myotonic the most common form among adults and Duchenne 
the most common form among children, primarily affecting males. MD is an incurable, often 
fatal disease. It is usually obvious by the age of 5 and evolves progressively until it causes 
disablement and death, around the age of 20. Death commonly results from involvement of 
the respiratory muscles. It is recessively inherited and linked to sex, and the gene determin-
ing DMD has been mapped in the Xp-21 locus. It has an incidence of 1/3000–1/3500 male 
births, and one third of the cases come from new mutation. Some affected individuals may 
develop intellectual disturbance due to unknown mechanism, so far. The sister of an affected 
individual has a 50% chance of carrying the defective gene. The result of the dystrophic locus 
on the gene is the absence of dystrophin, a rod-shaped protein that is part of the muscle 
cytoskeleton.
The genetic alteration produces abnormality in the membrane of the muscular fibers that con-
sists of a disturbance in the calcium transport (Ca2+), inside the muscular fibers, which is the base 
mechanism of cellular degeneration and necrosis. There is fiber necrosis and replacement of fibers 
by fat. A nucleotide degradation, and decreased muscle ATP and ADP content, has been reported. 
The ATP is necessary to drive the Na+/K+ pump, which maintains ionic gradients across the sar-
colemma; re-sequester the Ca2+ into the cisternae; and have power contraction. The production of 
ATP can be the result of anaerobic respiration, which breaks glucose down into ATP and lactic 
acid, or aerobic respiration when ATP, carbon dioxide, and water are formed. A second immediate 
reserve of energy exists in the form of creatine phosphate, which can donate phosphate to ADP 
to form ATP, becoming itself creatine. In the resting muscle, glucose is stored as glycogen, and in 
such a muscle aerobic respiration synthesizes ATP from glucose or fatty acids.
Therapy of DMD has been an elusive goal. Studies with isolated myocytes have shown that lipid 
peroxidation with an enhanced free radical production can be activated by increasing Ca concen-
tration. Low oxygen saturation in the muscle tissue may stimulate the Il-6 production, a cytokine, 
which is produced by contracting muscles and released into the blood. The blood circulation of 
the older Duchenne patients is particularly disturbed. Pedersen et al. [91] have demonstrated 
that Il-6 affects the metabolic genes, induction of lipolysis, inhibition of insulin resistance, and 
Reactive Oxygen Species and Selenium in Epilepsy and in Other Neurological Disorders
http://dx.doi.org/10.5772/intechopen.92003
171
stimulation of cortisol production. In addition, carbohydrate supplementation during exercise 
was shown to inhibit the release of Il-6 from contracting muscle. Thus carnitine supplementation 
is indicated to the Duchenne patients, to make sure that the energy supply will be good.
Johansson et al. [92] hypothesized that increased production of interleukin-6 (IL-6) and tumor 
necrosis factor-alpha (TNF-alpha) may be important underlying mechanisms in myotonic 
dystrophy. Patients with high body fat mass had significantly increased insulin levels and 
decreased morning levels of cortisol, ACTH, and testosterone. IL-6 and TNF-alpha levels are 
increased, and adrenocortical hormone regulation is disturbed in MD. Adiposity may con-
tribute to these disturbances, which may be of importance for decreased adrenal androgen 
hormone production and metabolic, muscular, and neuropsychiatric dysfunction in MD [92]. 
Henríquez-Olguín et al. [93] reported that IL-6 is a key metabolic modulator that is released 
by the skeletal muscle to coordinate a multisystemic response (liver, muscle, and adipocytes) 
during physical exercise; the alteration of this response in dystrophic muscles may contribute 
to an abnormal response to contraction and exercise.
Thus, several kinds of antioxidants have been proposed as a treatment since increased levels 
of thiobarbituric acid (TBA) reactive material have been found in the muscles and blood of 
DMD boys [94]. Increased amounts of pentane are expelled by the DMD patients [95]. We 
have previously reported that the biological half-life of 75Se in DMD patients was significantly 
shorter than in healthy controls [96]. We also reported that patients with myotonic muscular 
dystrophy, the most common form of muscular dystrophy in adults, show improvement in 
muscular force and function when treated with selenium and vitamin E [97].
Shimomura et al. [98] observed a group of trained animals, part of which were coenzyme 
Q10 treated and had to exercise for 30 min on treadmill, in downhill position. CoQ10-
treated animals had higher level of CoQ10 In their muscles, and the early rise in creatine 
kinase and lactic dehydrogenase plasma levels, due to the exercise, was evident at a 
remarkably significant lower extent, in the treated ones. Similar observations were also 
made in humans [99]. Therefore we have been treating the Duchenne patients with CoQ10. 
We have been given two siblings of whom the elder one got practically no antioxidants and 
the younger one whose antioxidant treatment started at the age of 6 years. Nutrient supple-
ment protocol for DMD patients included sodium selenite  0.05-0.1 mg Se kg−1 b.w. day−1 
; alpha-tocopherol, 10-20 mg kg−1 b.w. day−1;  vitamin B2, 0.2 mg kg−1 b.w. day−1;  vitamin 
B6, 5 mg kg−1 b.w. day−1; L-carnitine 10–20 mg kg−1 b.w. day−1; ubiquinone-10 (coenzyme 
Q10) 3 mg kg−1 b.w. day−1 [100]. In the future the therapy may be by producing functional 
amounts of dystrophin by skipping the mutated exon like what has been done in the mdx 
dystrophic mouse [101].
12. Personalized gene therapy
The analytical power of modern methods for DNA analysis has outstripped our capability to 
interpret and understand the data generated. It is vital that we understand the mechanisms 
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through which mutations affect biochemical pathways and physiological systems [102]: 
major bcr-abl mRNA nucleic acid amplification assay, genetic analysis of progressive mus-
cular dystrophy, genetic analysis of rearranged immunoglobulin gene, and genetic analy-
sis of malignant tumor. The promise of personalized medicines is enormous, particularly 
for rare disease [103, 104]. The genetic diversity of Emery-Dreifuss muscular dystrophy 
(EDMD) predicts that a cure will ultimately depend upon the individual’s defect at the 
gene level, making this an ideal candidate for a precision medicine approach [105]. Ataluren 
known as PTC124 is a drug for the treatment of Duchenne muscular dystrophy caused by 
a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF). 
PTC124 can lead to restoration of some dystrophin expression in human Duchenne mus-
cular dystrophy muscles with mutations resulting in premature stops [106]. Eteplirsen, a 
phosphoramidite morpholino sequence complementary to a portion of exon 51, is designed 
to force the exclusion of exon 51 from the mature DMD mRNA. Similar drugs targeting 
other DMD exons are under development and could theoretically restore reading frame 
in majority of patients. The fact that such drugs rely on specific sequence information and 
target the proximate cause of the disease makes these one of the first examples of precision 
genetic medicine [104, 107].
A common denominator to the spectrum of neurological disorders and selenium seems to 
be oxygen toxicity. Difficulties exist in giving proper weight to the interaction of the com-
ponents of a complex system like the brain’s antioxidant defense. The presence of multiple 
and contemporaneous control mechanisms means that a dysregulated system is impaired 
not only  in one but more regulatory or homeostatic mechanism. Supplementation by a 
single factor like selenium or together with other antioxidants may to a limited extent sus-
tain these mechanisms. However, much more basic research should be done before these 
complexities can be better understood. The neurological diseases reviewed above have 
provided the theoretical framework for the continued investigation of the efficacy of the 
pharmacological manipulation of glutathione concentration and synthesis in treatment of 
these diseases [108–110].
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DAT dementia of the Alzheimer type
LPO lipid peroxides
SOD superoxide dismutase
CAT catalase
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GSHPx glutathione peroxidase
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Cu-Zn SOD copper zinc superoxide dismutase
ROS reactive oxygen species
CNS central nervous system
DHP enzyme dehydropeptidase
TNF tumor necrosis factor
GR glutathione reductase
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NADPH nicotinamide adenine dinucleotide phosphate
GST glutathione-S-transferases
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·OH hydroxyl radical
E-GSHPx erythrocyte glutathione peroxidase
EEG electroencephalogram activation: EEG is an essential component in the 
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CSF cerebrospinal fluid
JNCL juvenile neuronal ceroid lipofuscinosis
MS multiple sclerosis
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